Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

Summary

This phase I trial studies the sides effects and best dose of pembrolizumab in treating participants with thymoma or thymic cancer that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Timeline

Start

2017-12-06

Primary completion

2027-12-31

Completion

2027-12-31

Drugs

Indications